News

Sistemic announces world-first with publication on the potential for patient stratification using a cell-based therapy for refractory rheumatoid arthritis

Release Date: January 9, 2017

Sistemic Ltd. announced today the publication of its ground-breaking research, undertaken together with TiGenix, identifying a set of circulating miRNA biomarkers which could potentially be used, if further clinically validated, to stratify refractory rheumatoid arthritis patients, prior to treatment, into responders and non-responders to an allogenic cell-based therapy:

Pages